CardiologyOnline.net

Cardiology Xagena

Currently available antiarrhythmic agents for the treatment of atrial fibrillation have important limitations, leaving an unmet need for safe and effective therapy. Ranolazine is an approved antiang ...


Dronedarone ( Multaq ) is a benzofuran derivative with a pharmacological profile similar to Amiodarone but has a more rapid onset of action and a much shorter half-life ( 13-19 h ). Researchers ha ...


With the introduction of novel oral anticoagulants ( NOACs ), the factors driving anticoagulant selection in atrial fibrillation ( AF ) in real-world practice are unclear. The goal was to examine ...


European Xarelto ( Rivaroxaban ) product information has now included guidance for use in patients with atrial fibrillation undergoing cardioversion. The label update is based on findings from the ...


A study has assessed the effect of Ranolazine, an anti-ischaemic agent with anti-arrhythmic properties, on the overall burden of atrial fibrillation in acute coronary syndromes ( ACS ) and has determi ...


X-VeRT is the first prospective randomized trial of a novel oral anticoagulant in patients with atrial fibrillation undergoing elective cardioversion. Researchers have assigned 1504 patients to Riv ...


Evidence is conflicting with regards to the role of vitamin D in statin induced myalgia ( SIM ). Studies so far have assessed cross-sectional association and were limited by study sample selected pred ...


A investigational IMPROVE-IT study has met its primary and all secondary composite efficacy endpoints. Treatment with Simvastatin in combination with Ezetimibe ( Vytorin ) has significantly reduced ca ...


The value of Aspirin ( Acetylsalicylic acid ) in primary prevention of cancer and cardiovascular disease ( CVD ) remains unclear. The aim of a study was to identify women who benefit from alternate- ...


It was hypothesized that in patients with stable coronary artery disease and stenosis, percutaneous coronary intervention ( PCI ) performed on the basis of the fractional flow reserve ( FFR ) would be ...


Ischemic mitral regurgitation is associated with increased mortality and morbidity. For surgical patients with moderate regurgitation, the benefits of adding mitral-valve repair to coronary-artery byp ...


Dual antiplatelet therapy is recommended after coronary stenting to prevent thrombotic complications, yet the benefits and risks of treatment beyond 1 year are uncertain. Patients were enrolled aft ...


Atrial fibrillation and heart failure often coexist, causing substantial cardiovascular morbidity and mortality. Beta-blockers are indicated in patients with symptomatic heart failure with reduced eje ...


Little is known in clinical practice about antiarrhythmic drugs ( AADs ) use in patients with atrial fibrillation ( particularly younger ones ) who do not have structural heart disease. Using the ...


Dronedarone ( Multaq ) is a non-iodinated benzofuran derivative with antiarrhythmic properties. In placebo-controlled atrial fibrillation trials, the drug was found to have divergent effects on endpoi ...


p38 MAPK inhibition has potential myocardial protective effects. Researchers have assessed Losmapimod, a potent oral p38 MAPK inhibitor, in patients with non-ST-segment elevation myocardial infarction ...


A study has evaluated the effect of Macitentan ( Opsumit ) on hospitalization of patients with symptomatic pulmonary arterial hypertension ( PAH ). PAH is a progressive, life-threatening disease ofte ...


Retrospective cohort study from a prospective data base has assessed new-onset postoperative atrial fibrillation in patients with esophageal and junctional cancer. Atrial fibrillation is common aft ...


Amiodarone ( Cordarone ) is an effective medication in preventing atrial fibrillation ( AF ), but it interferes with the metabolism of Warfarin ( Coumadin ). A study has examined the association of ...


Oral anticoagulant therapy with Rivaroxaban ( Xarelto ) is a safe alternative to Vitamin K antagonist ( VKA ) therapy in patients with atrial fibrillation who are undergoing elective cardioversion to ...


Flecainide ( Almarytm, Tambocor ) is frequently used for treatment of cardiac arrhythmias in children. Due to concerns regarding increased mortality, there has been hesitancy to use Flecainide in chil ...


Provocative testing with sodium channel blockers is advocated for the evaluation of unexplained cardiac arrest ( UCA ) with the primary purpose of unmasking the typical ECG features of Brugada syndrom ...


Symptoms are a major driver for patients with atrial fibrillation to seek medical attention and are important to titrate atrial fibrillation therapies. However, a large proportion of patients with atr ...


Antiarrhythmic drugs ( AADs ) and anticoagulation are mainstays of atrial fibrillation ( AF ) treatment. A study has assessed the use and outcomes of antiarrhythmic therapy in anticoagulated patients ...


The results of the phase IV ATLANTIC study, which indicates that the profile of Ticagrelor ( Brilinta, Brilique ) is comparable whether administered in a pre-hospital or in-hospital setting to ST segm ...


American Heart Association ( AHA ) and American College of Cardiology ( ACC ) have updated the guideline for the management of patients with non–ST-elevation acute coronary syndromes ( NSTE-ACS ). T ...


The vasodilator Cilostazol ( Pletal ), a phosphodiesterase-3 inhibitor, is approved in the United States for treatment of intermittent claudication. This study was aimed at evaluating its efficacy a ...


Women are more likely to develop anxiety and depression after a myocardial infarction than men, according to research presented at Acute Cardiovascular Care 2014, the annual meeting of the Acute Cardi ...


Elevated serum Digoxin concentration can cause toxicity, including death. Dronedarone ( Multaq ) increases Digoxin concentration by P-glycoprotein interaction. In PALLAS ( Permanent Atrial Fibrillat ...


The first in class angiotensin receptor neprilysin inhibitor, LCZ696 has been shown to reduce levels of N-terminal pro-brain natriuretic peptide ( NT-proBNP ), reduce left atrial size and improve New ...


Elevated high-sensitivity troponin is associated with increasing disease severity in patients with stable heart failure with reduced ejection fraction, but less is known about the association in heart ...


New data on investigational medicine, LCZ696, for patients with heart failure with reduced ejection fraction ( HFrEF ) have shown it has the potential to change the course of the disease for patients. ...


Eplerenone ( Inspra ) is the second MRA to be marketed in Canada after Spironolactone. Eplerenone has a Health Canada indication as an adjunct to standard therapy to reduce the risk of cardiovascular ...


Digoxin remains commonly used for rate control in atrial fibrillation, but very limited data exist supporting this practice and some studies have shown an association with adverse outcomes. Research ...


The coagulation system contributes greatly to the evolution of myocardial infarction ( MI ). Anticoagulation may reduce the occurrence of myocardial infarction as monotherapy or with concomitant use o ...


The comparative safety of Dabigatran ( Pradaxa ) versus Warfarin ( Coumadin ) for treatment of non-valvular atrial fibrillation in general practice settings has not been established. Researchers fo ...


A study has assessed safety and cardiovascular outcomes of Dronedarone ( Multaq ) in patients with paroxysmal or persistent atrial fibrillation ( AF ) with coronary heart disease ( CHD ). Coronary h ...


At the end of two previous trials, an excess of stroke and bleeding was observed in patients with atrial fibrillation randomized to a new oral anticoagulant ( NOAC ) who transitioned to a vitamin K an ...


Outcome data are limited on aortic valve replacement ( AVR ) in nonagenarian patients. This study reports the experience at Mayo Clinic ( Rochester, Minnesota, USA ) in the treatment of this elderly p ...


The myocardial effects of phosphodiesterase type 5 inhibitors ( PDE5i ) have recently received consideration in several preclinical studies. The risk/benefit ratio in humans remains unclear. Resear ...


Results of a pre-specified secondary analysis of the Eliquis Phase 3 AMPLIFY-EXT trial ( Apixaban after the initial Management ofPuLmonary embolIsm and deep vein thrombosis with First-line therapY-EXT ...


The American Association for Thoracic Surgery ( AATS ) has released new evidence-based guidelines for the prevention and treatment of perioperative and postoperative atrial fibrillation ( POAF ) and f ...


In the ONTARGET ( Ongoing Telmisartan Alone and in Combination with Ramipril Trial ) trial, dual agent renin-angiotensin-aldosterone system ( RAAS ) blockade with angiotensin-converting-enzyme inhibit ...


Ventricular fibrillation is one of the most serious complications of acute myocardial infarction, with a high mortality rate. There is a lack of value of rescue thrombolysis in ST-segment elevation my ...


IMPROVE-IT ( IMProved Reduction of Outcomes: VYTORIN Efficacy International Trial ), was an international, multi-center, randomised, double-blind active comparator trial of 18,144 high-risk patients p ...


Despite endorsement of Digoxin in clinical practice guidelines, there exist limited data on its safety in atrial fibrillation / atrial flutter. The goal of a study was to evaluate the association o ...


Post-thrombotic syndrome ( PTS ) is a common and burdensome complication of deep venous thrombosis ( DVT ). Previous trials suggesting benefit of elastic compression stockings ( ECS ) to prevent post- ...


Body-mass index ( BMI ) and diabetes mellitus have increased worldwide, whereas global average blood pressure and cholesterol have decreased or remained unchanged in the past three decades. Research ...


The outcome of patients with ruptured abdominal aortic aneurysm ( rAAA ) varies by country. Study of practice differences might allow the formulation of pathways to improve care. Data from the Hosp ...


Four new oral anticoagulants compare favourably with Warfarin ( Coumadin ) for stroke prevention in patients with atrial fibrillation; however, the balance between efficacy and safety in subgroups nee ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati